Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics
March 5, 2024 | AI, HEOR, Health Equity, Innovation, Market Access, Patient-centricity, Public health, artificial intelligence, drug approvals, drug pricing, ispor, precision medicine, public health policy, real-world evidence, value
Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each trend, sharing their perspectives on the topics in these areas (get ready – it’s a jam-packed read!).
Executive Summary
Hayley Shoel and Abigail Beveridge, from our Medical Writing Team, outline what to expect from this paper in the below Executive Summary.
In January 2024, ISPOR published their ‘2024–2025 Top HEOR Trends’ report, a horizon scanning publication that highlighted key trends affecting healthcare decision-making around the world.
Since these trends resonate with our own research and activities here at Mtech Access, experts within our team have come together to share their perspectives on each of the trends. In this article, we highlight considerations for Pharma and Medtech companies looking to optimise success in market access.
We begin with a look at how Real-World Evidence (RWE) is increasingly used for regulatory and reimbursement decision-making. The authors explain how data can be collected, and spotlight the frameworks available for guidance on optimising the use of RWE.
We particularly recommend the section on Artificial Intelligence (AI), a hot topic across all sectors. Likewise, don’t miss the Fostering Innovation section, where Phil Richardson (Chair & Chief Innovation Officer) shares his insights into the importance of innovation in healthcare. He highlights Mtech Access’ initiative, the ‘Above Brand Academy’, which aims to foster collaboration between the NHS, Pharma, Medtech, and market access, to identify innovative solutions to system-, therapy area-, and disease-level problems.
Samantha Gillard (Director – HTA) explores Accelerated Drug Approval Pathways and their associated challenges. She discusses how HEOR can aid with filling data gaps and the importance of considering the ‘fourth hurdle’ of recommendation for reimbursement.
Plus much more
Jump to a section:
- Real-World Evidence by Clare Foy (Director – Global Market Access) and Hanah Sfar-Gandoura (Senior Management Consultant – Innovation)
- Drug Pricing by Louise Maddison (Senior Consultant – Global Market Access)
- Artificial Intelligence by Richard Johnson (Senior Management Consultant – Innovation), Louise Maddison (Senior Consultant – Global Market Access), and Emily Hardy (Associate Consultant – Systematic Review)
- Fostering Innovation by Phil Richardson (Chair & Chief Innovation Officer)
- Health Equity by Chloe Morris (Associate Management Consultant – Innovation)
- Accelerating Drug Approvals by Samantha Gillard (Director – HTA)
- Value Measurement by Kaylie Metcalfe (Consultant – Health Economics)
- Patient Centricity by Louise Maddison (Senior Consultant – Global Market Access)
- Precision Medicine by Stephanie Swift (Senior Consultant – Systematic Review)
- Public Health Policy by Robert Hull (Senior Consultant – NHS Insight & Interaction)
Read the full paper at https://mtechaccess.co.uk/top-10-heor-trends-ispor-2024-25/
This content was provided by Petauri Evidence